**Lactobacillus brevis** Alleviates DSS-Induced Colitis by Reprograming Intestinal Microbiota and Influencing Serum Metabolome in Murine Model

Sujuan Ding¹, Yong Ma¹, Gang Liu¹,²*, Wenxin Yan¹, Hongmei Jiang¹ and Jun Fang¹*

¹ College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha, China, ² Hunan Provincial Key Laboratory of Animal Nutritional Physiology and Metabolic Process, CAS Key Laboratory of Agro-Ecological Processes in Subtropical Region, Institute of Subtropical Agriculture, Chinese Academy of Sciences, National Engineering Laboratory for Pollution Control and Waste Utilization in Livestock and Poultry Production, Changsha, China

The aim of this study was to examine the effects of *Lactobacillus brevis* on the microbial community and serum metabolome in colitis induced by dextran sulfate sodium (DSS). ICR mice were randomly distributed into three treatment groups: (i) *L. brevis* treatment alone (control), (ii) DSS administration alone, and (iii) treatment with *L. brevis* and DSS. Our results demonstrate that *L. brevis* treatment significantly alleviated DSS-induced body weight loss and colon inflammation. In addition, LC-MS analysis of serum metabolites revealed that *L. brevis* treatment increased the serum level of metabolites against inflammatory responses or oxidative stressors caused by DSS in the murine model. By detecting colonic microbiota, *L. brevis* increased colonic microbial diversity after challenging with DSS, and increased the relative abundance of Alloprevotella at genus, but Bacteroidales was reduced (*P* < 0.05). These results indicated that *L. brevis* could lower the severity of colitis induced by DSS via improving reprogramming the serum metabolome and intestinal microbiota. These findings suggest that the probiotic *L. brevis* may prevent tissue damage from colitis.

**Keywords:** colitis, murine, *Lactobacillus brevis*, intestinal microbiota, metabolome

**INTRODUCTION**

The regression of mucosal inflammation promotes the recovery of the epithelial barrier and proper tissue repair. It also restores normal organ function and steady-state microenvironment conditions (Leoni et al., 2015; Lopetuso et al., 2018). The pathogenesis of inflammatory bowel disease (IBD) is associated with dysfunction and a delay in mucosal healing (Neurath and Travis, 2012). Ulcerative colitis (UC) is a chronic IBD with unknown origin (Ng et al., 2013). Its recurrence and regression can severely affect patients’ quality of life. Despite efforts to reveal its pathogenesis and develop new therapies, UC remains a challenge for the medical and scientific communities (Detel et al., 2016).

Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits on the host (Hill et al., 2014). Indeed, it has long been proposed that the consumption of lactic acid bacteria in fermented products can improve health and longevity in humans.
The bacteria in the gut constantly interact with human cells in a variety of ways (Sekirov et al., 2010). It is widely established that the intestinal microbiota can regulate epithelial function, prevent pathogenic bacteria colonization, and affect immune responses (Martin et al., 2017). Several studies have revealed that Lactobacillus brevis KB290 can reduce the severity of colitis in murine models by increasing the ratio of CD11c+ MP dendritic cells to CD103+ dendritic cells in the colon (Fuke et al., 2018). Studies have also shown that L. brevis SBC8803 can regulate the expression of tumor necrosis factor α and interleukins 1b and 12 and improve the barrier function of the intestinal epithelium under oxidative stress. These results indicate that L. brevis SBC8803 contributes to the maintenance of intestinal homeostasis and can alleviate intestinal inflammation (Ueno et al., 2011). Moreover, a study has found that polyphosphate, an active substance from L. brevis, can down-regulate the expression of inflammatory and fibrosis-related molecules in intestinal epithelial cells to prevent inflammation and fibrosis (Kashima et al., 2015).

Metabolomic analysis is emerging as a powerful approach in system biology research because it provides unique insights into the understanding of organisms, disease diagnosis, pathology, and toxicology. Metabolomics can reveal the type of ongoing cellular processes in the organism by analyzing the chemical fingerprints of cells (Xu et al., 2012; Weng et al., 2015). For example, metabolomics analyses of serum samples from children with Crohn’s disease (CD) and UC have revealed that most of the chemically annotated metabolites belonged to the phospholipids and that they were reduced in CD and UC patients relative to healthy individuals subjects (Daniluk et al., 2019). In addition, the partial least-squares discriminant analysis (PLS-DA) load map of murine models of dextran sulfate sodium (DSS)-induced colitis showed that succinic acid, indole-3-acetic acid, glutamic acid, and glutamine are the main metabolites that separate the stages of colitis (Shiomi et al., 2011).

Currently, most probiotic strains are Lactobacilli and other lactic acid bacteria or Bifidobacteria (de Vrese and Schrezenmeir, 2008). There is mounting evidence that Lactobacillus can counteract intestinal inflammation, but the specific mechanism for such protection is unclear (Sung and Park, 2013). DSS-induced colitis in model animals has been shown to anthropize UC in diverse disease pathologies, ranging from disordered immune responses to clinical manifestations (Detel et al., 2016). Here, using a murine model, we aimed to investigate the effects of L. brevis on the severity of DSS-induced colitis and changes in the gut microbiota and the serum metabolome and to reveal the correlation between the intestinal microbiota and serum metabolites.

**MATERIALS AND METHODS**

**Bacteria Preparation**

Lactobacillus brevis stored in the Chinese Academy of Sciences Key Laboratory of Agro-ecological Processes in Subtropical Region (Changsha, China) were cultured in MRS broth (De Man, Rogosa, Sharpe) at 37°C for 24 h. Cultured bacterial fluid was cultured in MRS agar medium for 24 h at 37°C. Colonies were quantified, and the number of colonies per mL was determined. The bacteria samples were centrifuged at 5000 rpm for 10 min at 4°C. The pellet was resuspended in sterile normal saline solution at 2 to 5 × 10^10 CFU/mL.

**Animal and Experimental Design**

All animal procedures were approved by the Animal Ethics Committee of Hunan Agricultural University. Eight-week-old female ICR mice were purchased from SLAC Laboratory Animal Central (Changsha, China). DSS was purchased from Dalian Meilun Biotech., Co., Ltd. (M.W: 36000–50000, Dalian, China). All mice were housed in a pathogen-free mouse colony in a standard environment (temperature, 23°C ± 1°C; humidity, 50 ± 10%; 12-h alternating lighting cycles). After a 7-day adaptation period, the mice were randomly assigned to three groups of eight. The first group was treated with L. brevis (control), the second group was treated with 5% DSS (DSS), and the third group was treated with L. brevis and 5% DSS (LB-DSS). All mice had unlimited access to the basal diet feed and water. Our study lasted for a total of 19 days, the mice was administrated via intragastric administration with L. brevis or sterile saline, then DSS-treated group was given with 5% DSS in water from days 7 to 12, and continued to treat with L. brevis or sterile saline (12–19 days). At the end of the 19 days, the mice underwent 8 h of fasting, and blood samples were collected from the orbital blood vessels. The mice were then killed, and the colon lengths were measured. The middle part of the colon was then fixed using 4% formaldehyde. The colon samples were fixed using 4% formaldehyde, dehydrated with 5% DSS in water from days 7 to 12, and continued to treat with L. brevis or sterile saline (12–19 days). At the end of the 19 days, the mice underwent 8 h of fasting, and blood samples were collected from the orbital blood vessels. The mice were then killed, and the colon lengths were measured. The middle part of the colon was then fixed using 4% formaldehyde. The colon contents were collected, frozen in liquid nitrogen, and stored at −80°C. The final weight of the mice was recorded.

**Colonic Histopathology**

Colon samples were fixed using 4% formaldehyde, dehydrated using ethanol gradient, and embedded in paraffin, and 8-μm sections were stained with hematoxylin and eosin and viewed with an Olympus BX41 microscope (Münster, Germany).

Colon tissue samples were examined and graded according to the severity of inflammation as previously described (Vukelic et al., 2018). Histological examination showed that each colon tissue specimen was graded according to the severity of inflammation (no, 0; mild, 1; moderate, 2; severe, 3); inflammatory cell infiltration (normal, 0; mucosa, 1; mucosa with submucosa, 2; transmural extension of infiltration, 3); epithelial lesions (intact, 0; deformation of crypt structure, 1; erosion, 2; ulcer, 3); the degree of lesion (none, 0; point, 1; multifocal, 2; diffuse, 3); edema score (no, 0; mild edema of mucosa, 1; submucosa and mucosa, 2; whole wall of colon, 3). The final histologic injury score for the colon was the sum of the individual scores.

**Serum Metabolomic Analyses**

Serum samples were thawed slowly on ice. A 100-μL serum aliquot was added to 300 μL of methanol (Merck, Darmstadt,
and Colitis
Germany) and 10 µL of 2.8 mg/mL 2-Chloro-L-phenylalanine as internal standard (Sigma, St. Louis, MO). The mixture was briefly shaken for 30 s using a vortex and kept at −20°C for 1 h. They were then centrifuged at 12,000 rpm for 10 min at 4°C; and 200-µL aliquots of each of the sample supernatant were transferred into sampling bottles for analysis. Each sample was analyzed using a LC-MS analysis platform (Thermo Fisher Scientific, Ultimate 3000LC, Q Exactive) and a Hyper gold C18 (3 µm, 100 × 4.6 mm) column (Waters, Dublin, Ireland). The column temperature was maintained at 40°C and the flow rate at 0.35 mL/min. The automatic injector temperature was 4°C and the injection volume was 10 µL. The mobile phase was composed of 5% acetonitrile and 0.1% formic acid (A) (Merck) and acetonitrile with 0.1% formic acid (B). Gradient elution of the mobile phase is shown below: 0/5, 1/5, 2/40, 7/80, 11/95, 15.01/95, 15.5/5 and 19.5/5 (min/%B). The MS parameters were as follows, ESI+: Heater Temp = 300°C, Sheath Gas Flow rate = 45 arb, Aux Gas Flow Rate = 15 arb, Sweep Gas Flow Rate = 1 arb, spray voltage = 3.0 kV, Capillary Temp = 350°C, S-Lens RF Level = 30%; ESI−: Heater Temp = 300°C, Sheath Gas Flow rate = 45 arb, Aux Gas Flow Rate = 15 arb, Sweep Gas Flow Rate = 1 arb, spray voltage = 3.2 kV, Capillary Temp = 350°C, S-Lens RF Level = 60%. Data were extracted and analyzed according to a previous study (Ding et al., 2019).

16S Ribosomal RNA Amplicon Sequencing
Fecal samples were prepared for the MiSeq Library, followed by Illumina MiSeq 2 × 300 bp high throughput sequencing and bioinformatics analysis. Briefly, the cDNA library was constructed using a two-step PCR amplification method. Firstly, the target fragment was amplified using specific primers (inner primers) and recovered by glue. Then, the recovered product was used as the template for secondary PCR amplification (outer primers). The inner primer was F-(5′-TTC CCT ACA CGA CGC TCT TCC GAT CT-specific primer-3′) and R-(5′-GAG TTC CTT GGC ACC CGA GAA TTC CA- specific primer -3′), and the outer primers was F-(5′-GAT GAC GGC ACC ACC GAG ATC TAC AC- barcode – GTG ACT GGA GTT CCT TGG CAC CCG AGA-3′). All PCR products were recovered using AxyPrepDNA gel recovery kit (AXYGEN, Hangzhou, China), and quantitative analysis was conducted using FTC-3000 real-time PCR. The samples were mixed according to the molar ratio, and the library was prepared for standard Illumina sequencing using HiSeq2500 PE250 (Illumina, United States).

Correlation Analysis Between Serum Differential Metabolites and Colonic Microbiota
To explore the relationship between serum metabolic profiles and colonic microbiota in the development of DSS-induced colitis, Pearson correlation analysis was carried out using GraphPad Prism 7.00 for Windows software. Statistical significance was defined by a P-value of less than 0.05.

Data Analysis
All quantifications underwent analysis of variance to test the homogeneity of variance by Levene’s test and Student’s t-test (SPSS 21 software). Statistical significance was defined by a P-value of less than 0.05.

RESULTS
Lactobacillus brevis Counteracts DSS-Mediated Weight Loss and Colonic Injury in Mice
The mice were treated with or without L. brevis for 7 days, and then given 5% DSS for 5 days, followed by L. brevis treatment for another 7 days. The final animal weight, colon weight, and colon length were quantified (Figure 1). We observed that the mean weight of DSS mice was lower than those of control and LB-DSS mice (P ≤ 0.05), indicating that DSS treatment reduced overall body weight, and that L. brevis treatment counteracted DSS-mediated body weight loss. In addition, we observed no significant differences between the mean weights of control and LB-DSS mice, indicating that L. brevis did not affect the homeostatic body weight in the absence of DSS.

![Effects of L. brevis on DSS-induced colitis. (A) Final weight of the control, DSS, and LB-DSS mice. (B) Length of the colon of control, DSS, and LB-DSS mice. (C) Weight of the colon of control, DSS, and LB-DSS mice. *P < 0.05.](attachment:figure1.png)
**Lactobacillus brevis** Retards DSS-Induced Colitis

Histologic examination showed multiple erosive lesions and extensive inflammatory cell infiltration in the colon tissue of mice given with DSS. Infiltrated cells mainly consisted of macrophages, lymphocytes, neutrophils, and occasional eosinophils (Figure 2B). Intuitively, no lesions were observed in the colon tissue of control mice (Figure 2A). Although the colon tissue of LB-DSS mice showed some inflammatory lesions (Figure 2C), the severity of inflammation was less than that in the DSS mice ($P \leq 0.05$; Figure 2D).

**Lactobacillus brevis** Affects the Serum Metabolomic Profiles During Colitis

Principal component analysis (PCA) was used to determine the intrinsic similarity of spectral profiles (Figures 3B3,C3). Each scatterplot displays a serum sample in positive ion model (Figures 3A1,B1,C1) and negative ion model (Figures 3A2,B2,C2). This analysis was performed by Umetrics (Sweden). To reveal significant differences in metabolite abundance, two-group comparisons of the samples were conducted and analyzed using supervised multidimensional statistical method PLS-DA (Figures 3B2,B4,C2,C4). The variable importance in the projection (VIP $> 1.5$) of PLS-DA mode and $P$-values were used to identify metabolites that exhibited differential abundances (Table 1). A total of 22 metabolites were obtained, including 20 in the control vs. DSS comparison and 14 in the DSS vs. LB-DSS comparison. We found that the abundances of 2-hydroxyglutarate, epinephrine, oxalacetic acid, pyridine, guanosine, 6-methylthioguanosine monophosphate, N1-acetylspermidine, and ascorbic acid exhibited opposite trends in the control vs. DSS (increase) and DSS vs. LB-DSS (decrease) comparisons (Table 1). We found that the abundances of cholesterol acetate, tetrahydrocortisone, carnosic acid, and N-undecanoylglycine also exhibited opposite trends in the control vs. DSS (decrease) and DSS vs. LB-DSS (increase) comparisons (Table 1). In addition, we observed some unique metabolites, such as serotonin, 11-dehydrocorticoesterone, and indole (relative increase) and vitamin A2, gamma-linolenic acid, glycochenodeoxycholate-3-sulfate, arachidonic acid, and docosahexaenoic acid (relative decrease) in the control vs. DSS comparison. Lastly, two metabolites (7α-hydroxy-3-oxo-4-cholestenoate and 25,26-dihydroxyvitamin D) exhibited relative increases in the DSS vs. LB-DSS comparison.

**Lactobacillus brevis** Affects the Alpha Diversity in the Murine Colon During Colitis

The 16S rRNA in v3-v4 region extracted from the colonic samples were analyzed. The colonic microbiota diversity was determined using the Chao index, ACE index, Shannon index, and Simpson index (Figures 4A–D). We found that the colonic microbiota diversity decreased in DSS mice compared with the control mice. Importantly, LB-DSS mice exhibited higher Shannon and Simpson indices than the DSS mice ($P \leq 0.05$) (Figures 4C,D). Albeit insignificant, similar trends were observed for the Chao and ACE indices (Figures 4A,B). These results indicated that *L. brevis* prevented the loss of microbial diversity in the mouse colon after DSS challenge.

![FIGURE 2](https://www.frontiersin.org) Severity of colon tissue inflammation in mice given with DSS. Effects of *L. brevis* on colonic histology (A: control; B: DSS; C: LB-DSS), and corresponding histologic severity scores (D). *$P < 0.05$.*
**Lactobacillus brevis Affects Microbial Abundance at the Phylum Level During Colitis**

The dominant bacterial phyla observed in the mouse colon were Bacteroidetes, Firmicutes, Verrucomicrobia and Proteobacteria. They accounted for more than 97% of the microbiota. The proportion of Bacteroidetes was 41.09, 56.53, and 50.36%, that of Firmicutes was 22.75, 31.78, and 24.09%, that of Verrucomicrobia was 12.86, 7.87, and 5.04% in the control group, DSS group, and LB-DSS group, respectively (Figure 5A). Moreover, the relative abundance of Bacteroidetes was increased in the DSS group compared with the other two groups (Figure 5B), but there are no other differences (Figures 5C–E).

**Lactobacillus brevis Affects Microbial Abundance at the Order Level During Colitis**

The top ten most abundant microbial orders are shown in Figure 6A. The three most abundant bacteria were Bacteroidales, Clostridiales, Verrucomicrobiales, and Lactobacillales. The proportion of Bacteroidales is 56.41, 41.07, and 50.07%, that of Clostridiales was 15.38, 12.05, and 17.23%, that of Verrucomicrobiales is 12.86, 16.45, and 19.02%, that of Lactobacillales is 4.93, 11.16, and 3.10% in the control group, DSS group, and LB-DSS group, respectively (Figure 6A). Moreover, the relative abundance of Lactobacillales was lower in the DSS group than in the other two groups (Figure 6B), but there are no other differences (Figures 6C–E).

**Lactobacillus brevis Affects the Abundance of Microbial Genera During Colitis**

The top ten most abundant microbial genera were selected and made into bar percentage for analysis. The top three most abundant bacterial genera were found to be *Akkermansia*, *Bacteroides*, and *Lactobacillus*. The proportion of *Akkermansia* was 12.86, 16.45, and 19.02%, that of *Bacteroides* was 9.16, 12.05, and 17.23%, that of *Lactobacillus* was 4.06, 10.89, and 2.84% in the control group, DSS group, and LB-DSS group, respectively (Figure 7A). Moreover, the relative abundance of *Lactobacillus* was lower in the DSS group than in the other two groups (Figure 7B), but there are no other differences (Figures 7C–E).

**Correlation Between Serum Metabolites and Colonic Microbiota**

Pearson correlation is one of the most commonly used statistical analysis method (Hannigan and Lynch, 2013). The results of Pearson correlation (r) between metabolites and microbiota are shown in Figure 8. We found different levels of correlation in six groups of correlation analyses (P < 0.05): serotonin vs. Bacteroidetes (r = 0.472; P = 0.002; Figure 8A), serotonin vs. Bacteroidales (r = 0.47; P = 0.002; Figure 8B), serotonin vs. *Lactobacillus* (r = 0.669; P = 0.002; Figure 8C), arachidonic acid vs. Bacteroidetes (r = 0.648; P = 0.001; Figure 8D), arachidonic...
TABLE 1 | Metabolomic changes in serum of control, DSS, and LB-DSS mice.

| Metabolites                                      | Calc m/z | Control vs. DSS | DSS vs. LB-DSS |
|-------------------------------------------------|----------|-----------------|---------------|
|                                                  | (Log) FC | VIP             | P-value       | (Log) FC | VIP       | P-value |
| Cholesteryl acetate                              | 429.3727 | −1.55           | 1.87          | 0.00016 | ↓         | 1.58    | 1.73    | 0.00027 | ↑         |
| Serotonin                                        | 177.1022 | 1.10            | 1.52          | 0.00640 | ↑         | –       | –       | –       | –         |
| Vitamin A2                                       | 285.2213 | −1.22           | 2.01          | 0.00002 | ↓         | –       | –       | –       | –         |
| Gamma-linolenic acid                             | 243.2119 | −1.82           | 1.84          | 0.00026 | ↓         | –       | –       | –       | –         |
| 2-Hydroxymuconic acid                            | 149.0444 | 1.41            | 1.85          | 0.00023 | ↑         | –1.63   | 1.88    | 0.00004 | ↓         |
| Epinephrine                                      | 184.0968 | 1.12            | 1.93          | 0.00006 | ↑         | −1.18   | 1.70    | 0.00043 | ↓         |
| Tetrahydrocortisone                              | 365.2523 | −3.85           | 1.93          | 0.00007 | ↓         | 2.74    | 1.67    | 0.00058 | ↑         |
| Oxalactic acid                                   | 133.0131 | 1.09            | 2.01          | 0.00001 | ↑         | −1.54   | 2.05    | 0.00000 | ↓         |
| Glycochenodeoxycholate-3-sulfate                 | 530.2782 | −2.71           | 1.99          | 0.00002 | ↓         | –       | –       | –       | –         |
| Pyridine                                         | 80.0495  | 1.85            | 1.74          | 0.00136 | ↑         | −1.81   | 1.62    | 0.00128 | ↓         |
| 7α-Hydroxy-3-oxo-4-cholestenoate                  | 431.3156 | –               | –             | –       | –         | −1.28   | 1.58    | 0.00166 | ↓         |
| Arachidonic acid                                 | 305.2475 | −1.46           | 1.85          | 0.00024 | ↓         | –       | –       | –       | –         |
| Guanosine                                        | 284.0989 | 1.24            | 1.55          | 0.00487 | ↑         | −1.43   | 1.51    | 0.00021 | ↓         |
| Carnosic acid                                    | 297.1861 | −4.04           | 1.96          | 0.00004 | ↓         | 2.81    | 1.69    | 0.00046 | ↑         |
| Docosahexaenoic acid                             | 329.2475 | −1.47           | 1.89          | 0.00014 | ↓         | –       | –       | –       | –         |
| 6-Methylthioguanosine monophosphate              | 394.0581 | 1.52            | 1.51          | 0.00653 | ↑         | −1.63   | 1.66    | 0.00069 | ↓         |
| N-Undecanoylglycine                              | 244.1907 | −1.39           | 1.76          | 0.00066 | ^         | 1.22    | 1.65    | 0.00074 | ↑         |
| N1-Acetylspermidine                              | 188.1757 | 1.58            | 1.83          | 0.00028 | ↑         | −1.73   | 1.78    | 0.00012 | ↓         |
| 11-Dehydrocorticosterone                        | 345.206  | 1.56            | 1.64          | 0.00201 | ↑         | –       | –       | –       | –         |
| 25,26-dihydroxyvitamin D                         | 417.3363 | –               | –             | –       | –         | −1.33   | 1.53    | 0.00220 | ↓         |
| Indole                                           | 82.0451  | −1.35           | 2.01          | 0.00002 | ↓         | –       | –       | –       | –         |
| Ascorbic acid                                    | 177.0394 | 1.52            | 1.81          | 0.00036 | ↑         | −1.72   | 1.94    | 0.00001 | ↓         |
| N4-Acetylcytidine                                | 286.1034 | –               | –             | –       | –         | 1.06    | 1.74    | 0.00059 | ↑         |

Control vs. DSS, the control group compared with the DSS group; DSS vs. LB-DSS, the DSS group compared with LB-DSS group. FC, fold change (the ratio of mean metabolite levels between the groups), (Log) FC > 0 indicated a relatively higher concentration in the control or DSS group, while (Log) FC < 0 indicated a relatively lower concentration in the control or DSS group. VIP, variable importance in the projection; ↑/↓, increase/decrease; −, no changes. Significant threshold was set at VIP > 1.50 and P < 0.05.

acid vs. Bacteroidetes (r = 0.643; P = 0.001; Figure 8E), and N1-acetylspermidine vs. Lactobacillus (r = −0.498; P = 0.013; Figure 8F).

**DISCUSSION**

Inflammatory bowel disease patients are usually treated with anti-inflammatory, immunosuppressive, or biological agents, and some may even require surgery (Reid et al., 2011; Souza et al., 2015). Although these strategies can alleviate IBD symptoms, they do not provide permanent cure due to the cyclical and lifelong nature of IBD (Gareau et al., 2010). In recent years, an increasing body of evidence suggests that probiotics can prevent IBD in both experimental models and humans. In this study, our results reveal that L. brevis counteracted DSS-mediated body weight loss and inflammatory disruption of the colon in mice. In addition, L. brevis increased microbial diversity and the relative abundance of Bacteroidetes and Bacteroidales microbials in the colon after DSS challenge. In contrast, L. brevis treatment reduced the relative abundance of Alloprevotella microbials in the colon after DSS challenge. Metabolomic analysis showed that L. brevis treatment increased anti-inflammatory metabolites such as gamma-linolenic acid and carnosic acid and antioxidant metabolites such as ascorbic acid and 25,26-dihydroxyvitamin D in the serum.

The mammalian gastrointestinal tract is constantly exposed to a large number of bacteria, food, and environmental toxins (Kotula et al., 2014). The human intestinal mucosal surface is the largest body surface (~200–300 m²) that is in constant contact with the external environment (Lievein-Le Moal, 2013). The intestinal epithelium is lined by a single layer of columnar epithelial cells and is folded into concave or crypts. These fully differentiated epithelial cells act as physical and functional barriers to defend the body against potentially harmful microbes and viruses within the gut microenvironment (Lievein-Le Moal and Servin, 2006). Studies have shown that DSS can reduce body weight, increase intestinal permeability, ulceration, inflammatory cell infiltration, and goblet cell loss in murine models (Gadaleta et al., 2011). Another study showed that L. brevis G-101 given at a dose of 1 × 10⁸ CFU/per mouse can prevent weight loss, colon shortening, and inflammation in ICR mouse models after trinitrobenzene sulfonic acid treatment (Jang et al., 2013). In addition, heat-killed body of L. brevis SBC8803 can alleviate DSS-induced intestinal tissue injuries and improve survival in mice (Ueno et al., 2011). Our results here suggest that L. brevis counteracted DSS-mediated body weight loss.
FIGURE 4 | Diversity indexes of microbiota in the mouse colon. Venn plots depict the Chao index (A), ACE index (B), Shannon index (C), and Simpson index (D) of the colonic microbiota of the control, DSS, and LB-DSS mice. *P < 0.05.

and colon inflammation and injury without affecting colon length and weight.

Many microbes have been found to have stably colonized in our intestines for decades, but their relative abundances vary with our diets (Faith et al., 2013; David et al., 2014). In mice and humans, the abundance of the bacterial community can be significantly altered within 24 h of dietary changes (Wu et al., 2011; Holmes et al., 2017). These findings provide new insights into the treatment of IBD because the intestinal microbiota plays an important role in intestinal inflammatory responses, including changes in the relative abundance and diversity of intestinal microbiota immunity (Lepage et al., 2011; Dubin et al., 2016). In the T5KO mouse model of adherent-invasive Escherichia coli (AIEC)-induced chronic colitis, AIEC invasion of the intestine is associated with the reduction of the overall microbiota diversity (Chassaing et al., 2014). Bacteroides is the dominant phylum in infectious colitis. It is the most abundant bacterial phylum in the healthy population, and the decline of its relative abundance is related to obesity and chronic diarrhea in humans (Eckburg et al., 2005; Turnbaugh et al., 2009; Khoruts et al., 2010). Culture-based studies have reported an increase in the abundance of Bacteroidetes in the colonic mucosa of IBD patients (Wu et al., 2013). Our results showed that L. brevis protected the diversity of colonic microbial community and decreased the relative abundance of Bacteroidetes after DSS treatment. We found a lower relative abundance of Lactobacillales in DSS mice than in control mice. This may be because the length of time L. brevis colonized the colon does not necessarily include the time we collect colon contents. Therefore, even if L. brevis was given to the mice, it would not necessarily increase the relative abundance of Lactobacillales in the colon.

Metabolomic analysis provides data on all metabolic processes in cells and organisms (Shiomi et al., 2011). This quantitative analysis of metabolites is a promising method to identify biomarkers in IBD (Shiomi et al., 2011). In the control vs. DSS comparison, our results indicate that the concentrations of 2-hydroxyglutarate, epinephrine, oxalacetic acid, pyridine, guanosine, 6-methylthioguanosine monophosphate, N1-acetylspermidine, and ascorbic acid were higher and that those of cholesterol acetate, tetrahydrocortisone, carnosic acid, and N-undecanoylglycine were lower. However, these changes exhibited opposite trends in the DSS vs. LB-DSS comparison. The N1-acetylspermidine metabolites, which are related to amino acid metabolism and oxidative stress in cells, are polyamines derived from ornithine and methionine and play an important role in cell membrane stability, biosynthesis of signaling molecules, and cell growth and differentiation.
(Ramot et al., 2010; Liu et al., 2015). Arachidonic acid is the main precursor of eicosanoid mediators, and the abundance of this metabolite is greatly increased after cell activation (Calder, 2011). Some metabolites are related to inflammation, such as ascorbic acid and guanosine (Sorice et al., 2014; Bellaver et al., 2015). Monoamine serotonin [5-hydroxytryptamine (5-HT)] is an important regulator of gastrointestinal tract and other organ systems and is a neurotransmitter in the brain (Yano et al., 2015).

In summary, our study provides insights into the mitigative role of *L. brevis* in colitis by regulating the colonic microbial community and altering the serum metabolome. Specifically, *L. brevis* retarded the manifestation of colitis, such as body weight loss and colonic tissue damage. *L. brevis* also
improved the intestinal microorganism diversity, reduced the relative abundance of pathogenic bacteria, and altered the levels of serum metabolites. Our data indicate that the serotonin level was positively correlated with Bacteroidales and Lactobacillus abundances and negatively correlated with Lactobacillus abundance. The arachidonic acid level was negatively correlated with the abundances of Bacteroidetes and Bacteroidales, and the N1-acetylspermidine level was negatively correlated with the abundance of Lactobacillus. Serotonin plays an important role in gastrointestinal motility and intestinal dopaminergic neuron development, but its specific mechanism of influence is unknown. Taken together, our study demonstrates the feasibility and potency of using \textit{L. brevis} in the treatment of IBD.
and provides a basis for further investigation regarding *L. brevis* and colitis.

**DATA AVAILABILITY**

The data supporting this study can be found in NCBI using accession number SRP220500 (https://www.ncbi.nlm.nih.gov/sra/SRP220500).

**ETHICS STATEMENT**

All animal procedures were approved by the Animal Ethics Committee of Hunan Agricultural University.

**AUTHOR CONTRIBUTIONS**

SD and YM performed the study and conducted data analysis. GL and JF designed the research. WY provided assistance for the study. SD and YM prepared the first draft of the manuscript. All authors read and revised the manuscript.

**REFERENCES**

Bellaver, B., Souza, D. G., Bobermin, L. D., Goncalves, C. A., Souza, D. O., and Quincozes-Santos, A. (2015). Guanosine inhibits LPS-induced pro-inflammatory response and oxidative stress in hippocampal astrocytes through the heme oxygenase-1 pathway. *Purinergic Signal*. 11, 571–580. doi: 10.1007/s11302-015-9475-2

Calder, P. C. (2011). Fatty acids and inflammation: the cutting edge between food and pharma. *Eur. J. Pharmacol.* 668(Suppl. 1), 550–558. doi: 10.1016/j.ejphar.2011.05.085

Chassaing, B., Koren, O., Carvalho, F. A., Ley, R. E., and Gewirtz, A. T. (2014). AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. *Gut* 63, 1069–1080. doi: 10.1136/gutjnl-2013-304909

Daniluk, U., Daniluk, J., Kucharski, R., Kowalczyk, T., Pietrowska, K., Samczuk, P., et al. (2019). Untargeted metabolomics and inflammatory markers profiling in children with chrohn's disease and ulcerative colitis-a preliminary study. *Inflamm. Bowel Dis.* 25, 1120–1128. doi: 10.1093/ibd/iyz402

David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., et al. (2014). Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 505, 559–563. doi: 10.1038/nature12820

de Vrese, M., and Schrezenmeir, J. (2008). Probiotics, prebiotics, and symbiotics. *Adv. Biochem. Eng. Biotechnol.* 111, 1–66. doi: 10.1007/10-2008-0977

Detel, D., Buljic, S., Pucar, L. B., Kucic, N., Pugel, E. P., and Varlijen, J. (2016). Influence of CD26/dipeptidyl peptidase IV deficiency on immunophenotypic changes during colitis development and resolution. *J. Physiol. Biochem.* 72, 405–419. doi: 10.1007/s13105-016-0491-7

Ding, S., Fang, J., Liu, G., Veeramuthu, D., Naif Abdullah, A. D., and Yin, Y. (2019). The impact of different levels of cysteine on the plasma metabolomics and intestinal microflora of sows from late pregnancy to lactation. *Food Funct.* 10, 691–702. doi: 10.1039/c8fo01838c

Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., et al. (2016). Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. *Nat. Commun.* 7:10391. doi: 10.1038/ncomms10391

Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., et al. (2005). Diversity of the human intestinal microbial flora. *Science* 308, 1635–1638. doi: 10.1126/science.1110591

Faith, J. J., Gugure, J. L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A. L., et al. (2013). The long-term stability of the human gut microbiota. *Science* 341:1237439. doi: 10.1126/science.1237439

Fuke, N., Takagi, T., Higashimura, Y., Tsuiji, T., Umeda, R., Mizushima, K., et al. (2018). Lactobacillus brevis KB290 with vitamin a amelorates murine intestinal inflammation associated With the increase of CD11c+ macrophage/CD103-dendritic cell ratio. *Inflamm. Bowel Dis.* 24, 317–331. doi: 10.1093/ibd/izz003

Gadala, R. M., van Erpemap, K. J., Oldenburg, B., Willemsen, E. C., Renooij, W., Murzilli, S., et al. (2011). Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* 60, 463–472. doi: 10.1136/gut.2010.212159

Gareau, M. G., Sherman, P. M., and Walker, W. A. (2010). Probiotics and the gut microbiota in intestinal health and disease. *Nat. Rev. Gastroenterol. Hepatol.* 7, 503–514. doi: 10.1038/nrgastro.2010.117

Hannigan, A., and Lynch, C. D. (2013). Statistical methodology in oral and dental research: pitfalls and recommendations. *J. Dent.* 41, 385–392. doi: 10.1016/j.jdent.2013.02.013

Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., et al. (2014). Expert consensus document. the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat. Rev. Gastroenterol. Hepatol.* 11, 506–514. doi: 10.1038/nrgastro.2014.66

Holmes, A. J., Chew, Y. V., Colakoglu, F., Cliff, J. B., Klaassens, E., Read, M. N., et al. (2017). Diet-microbiome interactions in health are controlled by intestinal nitrogen source constraints. *Cell Metab.* 25, 140–151. doi: 10.1016/j.cmet.2016.10.021

Jiang, S. E., Hyam, S. R., Han, M. J., Kim, S. Y., Lee, B. G., and Kim, D. H. (2013). Lactobacillus brevis G-101 ameliorates colitis in mice by inhibiting NF-kappaB, MAPK and AKT pathways and by polarizing M1 macrophages to M2-like macrophages. *J. Appl. Microbiol.* 115, 888–896. doi: 10.1111/jam.12273

Kashima, S., Fujiya, M., Konishi, H., Ueno, N., Inaba, Y., Moriuchi, K., et al. (2015). Polysphosphate, an active molecule derived from probiotic *Lactobacillus brevis*, improves the fibrosis in murine colitis. *Transl. Res.* 166, 163–175. doi: 10.1016/j.trsl.2015.02.002

Khoruts, A., Dickson, V., Jansson, J. K., and Sadowsky, M. J. (2010). Changes in the composition of the human fecal microbiota after bacteriotherapy for recurrent clostridium difficile-associated diarrhea. *J. Clin. Gastroenterol.* 44, 354–360. doi: 10.1097/MCG.0b013e3181c87e02

Kotula, J. W., Kerns, S. J., Shaket, L. A., Siraj, L., Collins, J. J., Way, J. E., et al. (2014). Programmable bacteria detect and record an environmental signal in the mammalian gut. *Proc. Natl. Acad. Sci. U.S.A.* 111, 4838–4843. doi: 10.1073/pnas.1321321111

Leoni, G., Neumann, P. A., Sumagin, R., Denning, T. L., and Nusrat, A. (2015). Wound repair: role of immune-epithelial interactions. *Mucosal. Immunol.* 8, 959–968. doi: 10.1038/mi.2015.63

This research was supported by National Natural Science Foundation of China (Nos. 31772642 and 31672457), National Key Research and Development Program of China (2016YFD0500504 and 2016YFD0501201), Ministry of Agriculture of the People's Republic of China (2015-Z64 and 2016-X47), Local Science and Technology Development Project Guided by The Central Government (YDZZX2018430002303 and 2018CT5002), and Hunan Provincial Science and Technology Department (2017NK2322, 2018TP1031, 2016NK2101, 2016WK2008, 2016TP2005, and 2018WK4025), China Postdoctoral Science Foundation (2018M632963), and Double first-class construction project of Hunan Agricultural University (2019T120705 and SYL201802003).
Lepage, P., Hasler, R., Spehlmann, M. E., Rehman, A., Zvirblie, A., Begun, A., et al. (2011). Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. *Gastroenterology* 141, 227–236. doi: 10.1053/j.gastro.2011.04.011

Lievin-Le Moal, V. (2013). Dysfunctions at human intestinal barrier by water-borne protozoan parasites: lessons from cultured human fully differentiated colon cancer cell lines. *Cell Microbiol.* 15, 860–869. doi: 10.1111/cmi.12126

Lievin-Le Moal, V., and Servin, A. L. (2006). The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. *Clin. Microbiol. Rev.* 19, 315–337. doi: 10.1128/cmrr.19.2.315–337.2006

Liu, X., Liu, Y., Cheng, M., and Xiao, H. (2015). Metabolomic responses of human hepatocytes to emodin, aristolochic acid, and triptolide: chemicals purified from traditional chinese medicines. *J. Biochem. Mol. Toxicol.* 29, 533–543. doi: 10.1002/jbt.21724

Lopetuso, L. R., De Salvo, C., Pastorelli, L., Rana, N., Senkfor, H. N., Petito, V., et al. (2018). IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. *Proc. Natl. Acad. Sci. U.S.A.* 115, E9362–E9370. doi: 10.1073/pnas.1803613115

Martin, R., Chain, F., Miquel, S., Motta, J. P., Vergnolle, N., Sokol, H., et al. (2017). Using murine colitis models to analyze probiotics-host interactions. *FEMS Microbiol. Rev.* 41(Suppl. 1), S49–S70. doi: 10.1093/femsre/fux035

Neurath, M. F., and Travis, S. P. (2012). Mucosal healing in inflammatory bowel diseases: a systematic review. *Gut* 61, 1619–1635. doi: 10.1136/gutjnl-2012-302830

Ng, S. C., Tang, W., Ching, J. Y., Wong, M., Chow, C. M., Hui, A. J., et al. (2013). GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. *Biol. Pharm. Bull.* 36, 859–904. doi: 10.1248/bpb.36.859

Sekirov, I., Russell, J., and Granger, D. N. (2015). MyD88 mediates the protective effects of probiotics against the arteriolar thrombosis and leukocyte recruitment associated with experimental colitis. *Inflamm. Bowel Dis.* 21, 888–900. doi: 10.1097/mib.0000000000000331

Sung, M. K., and Park, M. Y. (2013). Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view. *World J. Gastroenterol.* 19, 994–1004. doi: 10.3748/wjg.v19.i7.994

Souza, D. G., Senchenkova, E. Y., Russell, J., and Granger, D. N. (2015). Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis of inflammatory bowel disease. *World J. Gastroenterol.* 21, 2225–2230. doi: 10.3748/wjg.v21.i6.21597

Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., et al. (2014). Ascorbic acid: its role in immune system and chronic inflammation diseases. *Mini Rev. Med. Chem.* 14, 444–452. doi: 10.2174/1389557514666140428112602

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.